PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19502172-7	2009	At weeks 2, 4 and 6, pGenesil-TGF-beta1-m1, pGenesil-TGF-beta1-m2 or pGenesil-TGF-beta1-m3 was injected by a hydrodynamics-based transfection method via the tail vein at 0.8 ml/10 g within 24 hours after injection of Con A in each of the three treatment groups.	pgenesil	21-29	transforming growth factor, beta 1	Mus musculus	30-39	
19502172-7	2009	At weeks 2, 4 and 6, pGenesil-TGF-beta1-m1, pGenesil-TGF-beta1-m2 or pGenesil-TGF-beta1-m3 was injected by a hydrodynamics-based transfection method via the tail vein at 0.8 ml/10 g within 24 hours after injection of Con A in each of the three treatment groups.	pgenesil	44-52	transforming growth factor, beta 1	Mus musculus	53-62	
19502172-7	2009	At weeks 2, 4 and 6, pGenesil-TGF-beta1-m1, pGenesil-TGF-beta1-m2 or pGenesil-TGF-beta1-m3 was injected by a hydrodynamics-based transfection method via the tail vein at 0.8 ml/10 g within 24 hours after injection of Con A in each of the three treatment groups.	pgenesil	44-52	transforming growth factor, beta 1	Mus musculus	53-62	
19502172-7	2009	At weeks 2, 4 and 6, pGenesil-TGF-beta1-m1, pGenesil-TGF-beta1-m2 or pGenesil-TGF-beta1-m3 was injected by a hydrodynamics-based transfection method via the tail vein at 0.8 ml/10 g within 24 hours after injection of Con A in each of the three treatment groups.	pgenesil	44-52	transforming growth factor, beta 1	Mus musculus	53-62	
19502172-7	2009	At weeks 2, 4 and 6, pGenesil-TGF-beta1-m1, pGenesil-TGF-beta1-m2 or pGenesil-TGF-beta1-m3 was injected by a hydrodynamics-based transfection method via the tail vein at 0.8 ml/10 g within 24 hours after injection of Con A in each of the three treatment groups.	pgenesil	44-52	transforming growth factor, beta 1	Mus musculus	53-62	
19502172-18	2009	There was no difference in the above parameters among the three treatment groups or between the control and model groups (P>0.05), but the inhibitory effect of pGenesil-TGF-beta1-m1 was the highest among the treatment groups.	pgenesil	163-171	transforming growth factor, beta 1	Mus musculus	172-181